Cabaletta Bio Toekomstige groei

Future criteriumcontroles 0/6

Cabaletta Bio zal naar verwachting groeien in winst en omzet met respectievelijk 1.2% en 84.2% per jaar. De winst per aandeel zal naar verwachting groeien met 11.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -81.8% zijn.

Belangrijke informatie

1.2%

Groei van de winst

11.2%

Groei van de winst per aandeel

Biotechs winstgroei	28.0%
Inkomstengroei	84.2%
Toekomstig rendement op eigen vermogen	-81.8%
Dekking van analisten	Good
Laatst bijgewerkt	05 Nov 2024

Recente toekomstige groei-updates

Recent updates

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Oct 22

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Sep 12

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

Jun 04

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Feb 11

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Oct 20

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Jul 07

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Mar 24

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 09

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Aug 05

Cabaletta Bio EPS beats by $0.08

May 03

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Apr 12

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

Feb 19

Chardan Capital initiates Cabaletta Bio with Buy rating

Jan 08

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Dec 28

Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder

Dec 09

Cabaletta Bio +5% on Q3 results, pipeline update

Nov 10

Winst- en omzetgroeiprognoses

NasdaqGS:CABA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	3	-159	-132	-107	6
12/31/2025	N/A	-135	-113	-103	7
12/31/2024	N/A	-114	-99	-91	7
6/30/2024	N/A	-90	-76	-74	N/A
3/31/2024	N/A	-77	-66	-65	N/A
12/31/2023	N/A	-68	-54	-54	N/A
9/30/2023	N/A	-62	-50	-49	N/A
6/30/2023	N/A	-57	-48	-47	N/A
3/31/2023	N/A	-56	-49	-46	N/A
12/31/2022	N/A	-53	-49	-46	N/A
9/30/2022	N/A	-51	-47	-45	N/A
6/30/2022	N/A	-51	-45	-43	N/A
3/31/2022	N/A	-50	-39	-38	N/A
12/31/2021	N/A	-46	-35	-34	N/A
9/30/2021	N/A	-42	-34	-33	N/A
6/30/2021	N/A	-39	-30	-29	N/A
3/31/2021	N/A	-36	-31	-31	N/A
12/31/2020	N/A	-33	-27	-27	N/A
9/30/2020	N/A	-29	-26	-25	N/A
6/30/2020	N/A	-26	-23	-23	N/A
3/31/2020	N/A	-21	-19	-19	N/A
12/31/2019	N/A	-22	-17	-16	N/A
9/30/2019	N/A	-19	-10	-10	N/A
6/30/2019	N/A	-23	-9	-9	N/A
3/31/2019	N/A	-21	-6	-6	N/A
12/31/2018	N/A	-12	-5	-5	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CABA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CABA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CABA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat CABA volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat CABA volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat CABA binnen 3 jaar verliesgevend zal zijn.

Cabaletta Bio Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 8.5% to US$30.38

Price target increased by 26% to US$17.00

Price target increased by 10% to US$14.17

Price target increased to US$9.00

Price target decreased to US$9.33

Price target decreased to US$10.60

Recent updates

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

New major risk - Revenue and earnings growth

New major risk - Share price stability

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

New major risk - Revenue and earnings growth

Cabaletta Bio, Inc., Annual General Meeting, Jun 03, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Cabaletta Bio, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

President of Science & Technology exercised options and sold US$204k worth of stock

Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

President of Science & Technology exercised options and sold US$230k worth of stock

President of Science & Technology notifies of intention to sell stock

Price target increased by 8.5% to US$30.38

Cabaletta Bio, Inc. Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

President of Science & Technology exercised options and sold US$136k worth of stock

Cabaletta Bio, Inc. Receives U.S. Food and Drug Administration Clearance of Investigational New Drug Application for Treatment of Systemic Sclerosis with CABA-201

President of Science & Technology notifies of intention to sell stock

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

President of Science & Technology exercised options and sold US$136k worth of stock

Cabaletta Bio, Inc. Appoints Shawn Tomasello to Its Board of Directors

President of Science & Technology notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target increased by 26% to US$17.00

President of Science & Technology exercised options and sold US$132k worth of stock

Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation

President of Science & Technology exercised options and sold US$238k worth of stock

Price target increased by 10% to US$14.17

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$9.00

High number of new and inexperienced directors

Co-Founder recently bought US$141k worth of stock

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio, Inc. Announces CABA-201, a Newly Designed, Fully Human CD19 Chimeric Antigen Receptor (CAR) Containing a 4-1Bb Co-Stimulatory Domain

Price target decreased to US$9.33

Price target decreased to US$10.60

Cabaletta Bio to Present Data At the 31St Eadv Congress and Provides Update on Descaartes™ Trial

We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully

Cabaletta Bio Presents Updated Interim Descaartes™ Trial Phase 1 Data At the Asgct 25Th Annual Meeting

Price target decreased to US$14.17

Cabaletta Bio, Inc. to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May

Price target decreased to US$15.67

High number of new and inexperienced directors

Cabaletta Bio, Inc., Annual General Meeting, Jun 01, 2022

Jakubowitz Law Reminds Cabaletta Bio, Inc. Shareholders of A Lead Plaintiff Deadline of April 29, 2022

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART

Pomerantz LLP Law Firm Announces the Filing of Class Action Against Cabaletta Bio, Inc., and Certain Officers

Co-Founder exercised options to buy US$144k worth of stock.

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

Price target decreased to US$18.83

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes Trial in Patients with mPV

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate

Cabaletta Bio, Inc.(NasdaqGS:CABA) dropped from Russell Microcap Value Index

Cabaletta Bio, Inc. Reports Acute Safety Data from the First Dose Cohort in DesCAARTes™ Trial

Cabaletta Bio EPS beats by $0.08

Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans

What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?

New 90-day low: US$12.20

Chardan Capital initiates Cabaletta Bio with Buy rating

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Cabaletta Bio Announces First Patient Dosed in DesCAARTes Trial of Dsg3-Caart for Treatment of Mucosal-Dominant Pemphigus Vulgaris